Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,471
Recruiting: 1,282
Ph III recruiting: 129
Growth YoY: +2.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,643)

clinicaltrialsPublishedShowing 351–400 of 2,097 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04847050	A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy	completed	Phase 2	19	National Cancer Institute (NCI)NIH	1	Aug 27, 2024	clinicaltrials
NCT02191930	Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma(BVB)	completed	Phase 2	70	University of CologneOTHER